Search for Clinical Trial Results

Sponsored By

Mucopolysaccharidosis I - 57 Studies Found

Status Study
Active, not recruiting Study Name: Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)
Condition:
  • Morquio A Syndrome
  • Mucopolysaccharidosis IV A

Date: 2014-08-01
Withdrawn Study Name: Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa
Condition:
  • Mucopolysaccharidosis IV
  • Morquio A Disease

Date: 2014-05-28
Completed Study Name: Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
Condition:
  • Morquio Syndrome A
  • Maroteaux Lamy Syndrome
  • MPS IVA
  • Morquio Syndrome

Date: 2013-08-08
Completed Study Name: A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Condition:
  • Mucopolysaccharidosis IV Type A
  • Morquio A Syndrome
  • Date: 2014-10-28
    Interventions: Drug: Vimizim® (elosulfase alfa) Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
Completed Study Name: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Condition:
  • Mucopolysaccharidosis IV A
  • Morquio A Syndrome
  • Drug: BMN 110 - Weekly

Terminated Study Name: A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Condition:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

    • Date: 2008-11-06
Completed Study Name: A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Condition: MPS IV A
Date: 2011-01-10
Interventions:
  • Drug: BMN 110 Weekly BMN 110 W
Approved for marketing Study Name: BMN 110 US Expanded Access Program
Condition:
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome
  • MPS IVA

    • Date: 2013-05-15
    Interventions: Drug: BMN 110
Terminated Study Name: A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Condition:
  • MPS IV A
  • Mucopolysaccharidosis IVA
  • Morquio A Syndrome

    • Date: 2010-10-28
    Interventions: Drug: BMN 110 Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of
<<< Previous | Next >>>